Peroxisome proliferator-activated receptor gamma (PPARg) is thought to play a role in sebaceous gland cell function. We previously demonstrated in human epidermoid carcinoma KB cells that UVB irradiation activates PPARg via the generation of multiple oxidized glycerophosphocholine species with PPARg ligand activity. UVBinduced cyclooxygenase 2 (COX-2) expression was also shown to be PPARg-dependent. We therefore reasoned that PPARg activation and PPARg-dependent COX-2 expression may occur as a general consequence of oxidative stress. The present studies were designed to examine the effects of the oxidant tert-butylhydroperoxide (TBH) on PPARg activation and COX-2 expression in SZ95 sebocytes. We first verified that functional PPARg is expressed and activated by UVB irradiation in these cells. We next demonstrated that TBH increased PPARg reporter activity in SZ95 sebocytes. Increased COX-2 protein, mRNA expression, and prostaglandin E 2 (PGE 2 ) production was observed after TBH or PPARg agonist treatment. The ability of PPARg agonists and TBH to induce COX-2 expression and PGE 2 production was blocked by pretreatment with the specific PPARg antagonist GW9662. Finally, TBH and PPARg agonists failed to elicit a PGE 2 response in SZ95 sebocytes stably expressing a dominant-negative PPARg. This study illustrates the importance of the PPARg system in regulating cellular responses to oxidative stress.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) were first cloned in the early 1990s. They were identified as targets of various xenobiotic and oxidized lipid molecules that are involved in regulating the formation of intracellular organelles, called peroxisomes, which are involved in lipid metabolism (reviewed in Kuenzli and Saurat, 2003) . PPARs are members of the ligand-activated nuclear hormone receptor superfamily, which include receptors for thyroid hormones, retinoids, steroid hormones, and vitamin D. Three different PPAR subtypes have been cloned: PPARa, PPARb/d, and PPARg. All are nuclear transcription factors that require heterodimerization with the retinoid X receptors for transcriptional activity. Upon heterodimerization, PPAR:retinoid X receptor heterodimers activate transcription by binding to specific DNA sequences, called peroxisome proliferators response elements (PPRE), in the promoter region of target genes.
Natural PPARg ligands are thought to include metabolites of both cyclooxygenase (COX) and lipooxygenase pathways, including the cyclopentanone prostaglandin (PG), 15-deoxy-D 12,14 -prostaglandin J2, and the 13-hydroxyoctadecadienoic acid. However, the high concentrations needed to activate PPARg, as well as nonspecific effects, raise doubts as to the physiological relevance of these agents. More recently, it has been determined that the oxidized alkyl phospholipid, 1-hexadecyl 2-azelaoyl phosphatidylcholine (azPC), which is derived from oxidized low-density lipoprotein, may represent an endogenous, physiologically relevant, PPARg ligand with an EC 50 of approximately 40 nM (Davies et al., 2001) . Within cells, azPC is also derived from oxidation of 1-hexadecyl 2-arachidonoyl-glycerophosphocholine, a minor constituent of cellular lipids (Zhang et al., 2005) . Importantly, we have previously demonstrated that azPC is produced following UVB irradiation of 1-hexadecyl 2-arachidonoyl-glycerophosphocholine (Zhang et al., 2005) . In addition, a number of synthetic PPARg agonists have been developed that are widely used in the treatment of type II diabetes. This thiazolidinedione class of antidiabetic compounds includes the potent PPARg ligand ciglitazone.
PGs are lipid mediators synthesized in response to numerous growth factors and environmental stimuli. The production of PGs is dependent on the activity of COX enzymes (COX-1 and COX-2) (Ota et al., 2002) . COX-1 is generally constitutively expressed, whereas COX-2 is induced by various mitogens, hormones, and environmental stimuli. Increased COX-2 expression and elevated prostaglandin E 2 (PGE 2 ) are commonly observed in epithelial malignancies (Buckman et al., 1998; Nijsten et al., 2004) . PGs and COXs are important in epithelial tumorigenesis, as demonstrated by the potent chemopreventive capacity that COX inhibitors exert in various malignancies, including skin cancer (Fischer et al., 1999; Pentland et al., 1999; Ota et al., 2002) . Finally, although the COX-2 promoter is known to contain a 5 0 -PPRE, its role in regulating COX-2 mRNA expression has only recently been examined (Pontsler et al., 2002) .
We have recently demonstrated, in the epidermoid carcinoma cell line (KB), that UV exposure results in the production of oxidized lipid species, including azPC, with potent PPARg ligand activity (Zhang et al., 2005) . As this activity was blocked by treating cells with the antioxidant, Trolox s , this strongly suggests that PPARg agonist activity occurred as a result of UV-generated reactive oxygen species. In addition, we demonstrated that PPARg activation in KB cells is an essential step in UVB-induced COX-2 expression. We therefore hypothesized that PPARg activation and PPARgmediated induction of COX-2 may occur as a generalized response to other types of oxidative stress.
As PPARg is prominently expressed in the pilosebaceous glands and in SZ95 sebocytes, we therefore chose to examine this hypothesis in the SZ95 sebaceous gland cell line (Chen et al., 2003; Alestas et al., submitted for publication) . In addition, the most common disease of the pilosebaceous gland is acne vulgaris, the pathogenesis of which is dependent on ductal hyperplasia and hyperkeratinization, excess sebum production, inflammation, and the presence of propionibacteria (Harper and Thiboutot, 2003; Holland et al., 2004; Zouboulis et al., 2005) . Given that PPARg and COX-2 are known to be involved in inflammation and sebocyte growth and differentiation, it is likely that a PPARg-COX-2 signaling system would play an important role in sebocyte biology and pathology (Rosenfield et al., 1998 (Rosenfield et al., , 2000 Kim et al., 2001; Downie et al., 2004; Kuenzli and Saurat, 2004; Iwata et al., 2005) .
The importance of COX-2 in sebaceous gland development is seen in transgenic mice with targeted overexpression of the inducible COX-2 isoform (Neufang et al., 2001; Muller-Decker et al., 2002) . These mice develop sebaceous gland hyperplasia, sebaceous gland adenomas, and increased sebum production, suggesting an important role for COX-2 and PGs in sebocyte proliferation, lipid metabolism, and tumorigenesis. We therefore sought to determine whether oxidative stress induces PPARg activation and increased COX-2 expression and activity in human sebocytes in vitro.
RESULTS

Identification of functionally active PPARc protein in epidermal cells
It has previously been reported that SZ95 sebocytes express PPARg protein (Chen et al., 2003) . PPARg1 and PPARa are the most abundant PPAR isoforms in SZ95 sebocytes (Alestas et al., submitted for publication). Thus, the first studies were designed to confirm that SZ95 sebocytes contain the functional PPARg system. Total cellular protein was isolated and PPARg protein was shown to be present in SZ95 cell lines (Figure 1a) . Primary human keratinocytes and human epidermal carcinoma cells (KB cells) were also examined as these cells have also been reported to express PPARg (Rosenfield et al., 2000; Zhang et al., 2005) . We next sought to determine whether PPARg was functionally active in SZ95 sebocytes. To accomplish this, we transfected SZ95 sebocytes with a PPRE-luciferase reporter construct (Davies et al., 2001) . In Figure 1b , we show that the specific PPARg agonists azPC and ciglitazone were able to induce agonist-dependent luciferase expression in SZ95 sebocytes (Figure 1b ). It should be noted that the PPRE reporter used does not result in high levels of promoter activity (only 2-to 3-fold increases), findings consistent with the use of this gene reporter system in other cell types (Davies et al., 2001; Zhang et al., 2005) .
PPARc activation is sufficient to induce COX-2 expression in SZ95 sebocytes
In previous studies using KB cells, we demonstrated that PPARg agonists were capable of augmenting phorbol esterinduced COX-2 expression (Zhang et al., 2005) . However, PPARg agonists alone had no effect on COX-2 expression in these cells.
In contrast, we demonstrate in Figure 2a that the addition of ciglitazone or azPC alone is sufficient to induce COX-2 expression in the absence of phorbol ester. For these studies, SZ95 sebocytes were treated with ciglitazone, azPC, or phorbol-12-myristate-13-acetate (PMA) as a positive control for induction of COX-2. To confirm that PPARg agonist-induced COX-2 induction was due to PPARg activation, the specific PPARg inhibitor GW9662 was used (Leesnitzer et al., 2002) . Significantly, pretreatment of SZ95 sebocytes with the PPARg antagonist GW9662 blocked the ability of ciglitazone to augment COX-2 expression ( Figure  2b ). In contrast, pretreatment with GW9662 did not alter PMA-induced COX-2 expression.
UVB irradiation of SZ95 sebocytes produces PPARc agonistic activity that is transferable in cellular homogenates
We have previously demonstrated, in human epidermoid carcinoma KB cells, that UVB irradiation could induce the generation of lipid species with PPARg agonist activity (Zhang et al., 2005) . We therefore examined whether UVB irradiation of SZ95 sebocytes would result in a similar production of a dose-dependent PPARg agonist activity that could be transferred via cellular homogenates. In Figure 3a and b, we demonstrate that homogenates prepared from UVBirradiated SZ95 sebocytes contained potent PPARg agonist activity, with a dose of 4,000 J/m 2 inducing luciferase activity at levels equivalent to 20 mM ciglitazone. This was shown in both SZ95 sebocytes and KB cells expressing the PPREluciferase reporter.
The potent oxidant tert-butylhydroperoxide generates a PPARc agonistic activity in SZ95 sebocytes
We have previously demonstrated that oxidative stress mediated by UVB exposure induces PPARg ligand production in KB cells. In Figure 4 , we demonstrate that this effect Approximately 40 mg cellular protein was isolated and separated on 10% SDS-PAGE; COX-2-immunoreactivity was determined using a polyclonal antibody. (b) SZ95 sebocytes were pretreated with vehicle control or 1 mM GW9662 (GW) for 1 hour, and then treated with 20 mM ciglitazone or 100 nM PMA. Forty micrograms of cellular protein was isolated and separated on 10% SDS-PAGE and COX-2 immunoreactivity was determined using a polyclonal antibody. appears to be common to different oxidative stressors. In this case, the lipid-soluble oxidant tert-butylhydroperoxide (TBH) was capable of generating a dose-dependent PPARg agonistic activity. Doses of 10-20 mM resulted in PPRE-luciferase activity equivalent to that observed for the PPARg agonist ciglitazone.
Both ciglitazone and TBH induce COX-2 mRNA in a PPARc-dependent manner
Previous studies have reported that the COX-2 promoter contains a known PPRE consensus site (Meade et al., 1999) . Thus, the next studies were designed to determine whether the treatment of SZ95 sebocytes with the oxidative stressor TBH would induce PPARg-dependent COX-2 mRNA expression. In Figure 5 , we utilized quantitative RT-PCR to demonstrate that ciglitazone, as well as TBH treatment, induced COX-2 mRNA expression in SZ95 sebocytes. This induction of COX-2 mRNA by ciglitazone was completely blocked by pretreatment of PPARg-specific antagonist GW9662. GW9662 was also able to inhibit TBH-induced COX-2 expression significantly.
PPARc activity is critical for oxidative stress-induced PGE 2 production in SZ95 sebocytes
Previous studies in KB cells indicated that UVB-induced epidermal PGE 2 formation is dependent on the PPARg system (Zhang et al., 2005) . In Figure 6 , we demonstrate that the PPARg agonist ciglitazone as well as oxidative stressors TBH and UVB were able to significantly increase PGE 2 production over 8 hours in SZ95 sebocytes. The calcium ionophore A23187, which induces calcium-dependent eicosanoid synthesis, was used as a positive control. Importantly, the PPARg antagonist GW9662 was able to block PPARg agonist and oxidative stress-induced PGE 2 production, but not ionomycin-induced PGE 2 production. There was no significant stimulation of PGE 2 production by the selective PPARa agonist (WY14643, 20 mM) or the specific PPARb/d agonist (GW501516, 500 nM) (data not shown). We next sought to use a molecular approach to verify that the PPARg system was indeed involved in oxidative stress-mediated COX-2 induction and PGE 2 production. To accomplish this, SZ95 sebocytes stably expressing a PPARg dominant-negative mutant construct were produced. For control cells, cells expressing the empty vector (pcDNA3) were also produced. To verify that the stable SZ95/DPPARg dominant-negative cells lacked PPARg activity, we transiently transfected the cells with the PPARg-dependent luciferase reporter. The DPPARg-expressing cells lacked luciferase reporter expression in response to ciglitazone or azPC (data not shown). As shown in Figure 7 , ciglitazone, TBH, or UVB irradiationinduced PGE 2 production was markedly suppressed in SZ95/ DPPARg dominant-negative cells in comparison to SZ95/ pcDNA3 control cells. In contrast, PGE 2 production induced by calcium ionophore A23187 was not affected by the presence of a mutant PPARg system. Altogether, these studies confirm that the PPARg system, activated by specific agonists or agonistic activity generated by oxidative stress, can modulate COX-2 expression and PGE 2 production in SZ95 sebocytes. . Specific PPARc antagonist GW9662 blocks oxidative stressinduced COX-2 mRNA induction. SZ95 sebocytes were pretreated with vehicle control or 1 mM GW9662 for 1 hour, and then exposed to 20 mM ciglitazone, 10 mM TBH, or 100 nM PMA for 6 hours. Figure 6 . Specific PPARc antagonist GW9662 blocks oxidative stressinduced PGE 2 production. SZ95 sebocytes were pretreated with vehicle control or GW9662 1 mM for 1 hour, and then treated with 20 mM ciglitazone, 10 mM TBH, 500 nM calcium ionophore A23187, or exposed to 600 J/m 2 UVB irradiation; PGE 2 production was assayed in the tissue culture supernatants after 8 hours. The values of PGE 2 expression shown are mean7SD and are representative of three independent experiments (*Po0.05).
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DISCUSSION
We have previously reported that UVB exposure activates PPARg via production of multiple mostly uncharacterized oxidized glycerophosphocholine species. Importantly, one of these oxidized lipids was identified as azPC, which has previously been identified as an endogenously produced PPARg ligand. In addition, COX-2 is well known to be induced in the epidermis by UVB treatment. Importantly, we demonstrated that UVB-mediated COX-2 induction is mediated by PPARg activation. In this report, we further extend these studies to show that PPARg is activated as a general response to multiple oxidative stressors, including the application of the lipid-soluble oxidizing agent TBH. In addition, both ciglitazone and azPC were capable of inducing COX-2 expression in SZ95 sebocytes in the absence of a costimulatory signal. This differs from our previous findings in KB epidermal carcinoma cells, in which COX-2 induction by PPARg agonists required a costimulation with phorbol ester or IL1-b. Our data add to a growing body of evidence that PPARg activation can act to either induce and repress COX-2 expression in a cell-and tissue-type-specific manner (Meade et al., 1999; Liang et al., 2001; Yang and Frucht, 2001; Pontsler et al., 2002; Bishop-Bailey and Warner, 2003; Hinz et al., 2003; Mendez and LaPointe, 2003; Sabichi et al., 2004) . These data add a stone to the mosaic of PPARg relevance to sebocyte biology. Natural and synthetic PPAR-g1 ligands have been shown to both enhance and reduce lipogenesis in sebaceous gland cells or isolated human sebaceous glands (Rosenfield et al., 1998; Downie et al., 2004; Iwata et al., 2005) . In addition, in mouse epidermis, overexpression of COX-2 is associated with a cutaneous phenotype demonstrating sebaceous gland hypertrophy and greasy hair, suggestive of increased sebum production (Neufang et al., 2001; Muller-Decker et al., 2002) . Thus, our findings that PPARg activation induces COX-2 expression in SZ95 sebocytes may indicate a PPARg/COX-2-mediated pathway regulating sebocyte proliferation and/or lipogenesis. These data fit well with the clinical finding that COX-2 expression is upregulated in the sebaceous glands of acne-involved skin (Alestas et al., submitted for publication).
Diseases of the pilosebaceous gland include the common disease acne vulgaris. Although not life-threatening, acne can result in facial scarring and even relatively minor acne is significantly associated with psychosocial well-being, including lowered self-esteem, increased levels of anxiety and depression, and increased suicidal ideation (Gupta and Gupta, 2003; Yazici et al., 2004) . It is interesting that two well-known treatments for acne are retinoids and benzoyl peroxide, which induces lipid peroxidation in keratinocytes (Babich et al., 1996) . Given that PPARs heterodimerize with retinoid X receptors and oxidative stress activates a PPARg--COX-2 signaling pathway, this strongly suggests that the PPARg-COX-2 signaling pathway may play a role in acne pathogenesis.
In addition to sebaceous gland hypertrophy, mice overexpressing COX-2 in the skin also exhibited increased rates of sebaceous gland adenomas (Neufang et al., 2001; MullerDecker et al., 2002) . Although uncommon, sebaceous carcinoma is an aggressive carcinoma, with frequent local and distant metastasis at the time of diagnosis (Omura et al., 2002; Bordea et al., 2004) . Moreover, the chronic use of strong oxidants like benzoyl peroxide is also associated with increased risk for cutaneous neoplasia (Athar et al., 1989) . Given the growing evidence that COX-2 plays a causal role in epithelial tumorigenesis, it is unclear whether chronic or repeated benzoyl peroxide exposure may increase the risk for neoplastic disease in the pilosebaceous gland or surrounding epidermis via PPARg stimulation and subsequent COX-2 elevation.
In conclusion, we show clear evidence in a second independent cell line that PPARg is activated by UVB irradiation. Moreover, activation of PPARg appears to occur as a general response to oxidative stress, as the potent lipidsoluble oxidant TBH was also capable of activating PPARg. In addition, we show that the ability of oxidative stress to induce COX-2 expression is PPARg dependent. However, the ability of PPARg agonists to stimulate COX-2 expression in the absence of costimulatory signals appears to be dependent on cell type. In addition, it is unclear whether oxidative stress would act to suppress COX-2 expression in those cells or tissues in which PPARg agonists have been shown to inhibit COX-2 expression. It does seem apparent, however, that the mechanisms by which PPARg acts to regulate COX-2 expression are likely to be complex. Not surprisingly, COX-2 expression is influenced by multiple mechanisms, including both positive and negative transcriptional regulators, mRNA stability, and translational silencing (Matsuura et al., 1999; Meade et al., 1999; Dixon et al., 2000 Dixon et al., , 2003 .
MATERIALS AND METHODS
Chemicals
All chemicals were obtained from Sigma (St Louis, MO), unless otherwise indicated. PMA was obtained from Sigma (St Louis, MO). Ciglitazone was from Alexis Biochemicals (San Diego, CA). azPC was from Avanti s Polar Lipids Inc. (Alabaster, AL). The PPARgspecific antagonist GW9662 was purchased from Cayman Chemical (Ann Arbor, MI). TBH was from MP Biomedicals Inc. (Aurora, OH).
Cell culture
The cells of the SZ95 sebaceous gland cell line are human sebocytes immortalized by stably transfecting a primary human facial sebocyte culture with the SV-40 large T antigen (Zouboulis et al., 1999) . Significantly, SZ95 sebocytes retain the culture morphology of primary sebocytes as well as sebocyte-specific marker expression. In addition, normal lipid production is observed, with both primary sebocytes and SZ95 sebocytes producing a large number of cytoplasmic lipid vacuoles composed of neutral lipids, including sebum-specific lipids (Zouboulis et al., 1999) . SZ95 sebocytes were grown in Sebomed s medium (Biochrom, Berlin, Germany) supplemented with 10% fetal bovine serum (Intergen, Purchase, NY) and 5 ng/ml epidermal growth factor (R&D Systems, Minneapolis, MN). The SZ95/PPARg dominant-negative model was created by transfection of SZ95 sebocytes with the PPARg dominant-negative construct (DPPARg) encoding the mutant human PPARg with two point mutations in the AF-2 domain, L466A and E469A (a kind gift from Dr VKK Chatterjee, University of Cambridge, Cambridge, UK). The human epidermoid carcinoma (KB) cells were cultured as described previously (Zhang et al., 2005) .
PPRE-luciferase reporter assay
The PPRE-luciferase reporter assay was carried out essentially as described previously (Zhang et al., 2005) .
UV irradiation studies
SZ95 cells were irradiated with UVB as previously described (Zhang et al., 2005) . The UV source was a Philips F20T12/UV-B lamp (270-390 nm; containing 2.6% UVC, 43.6% UVB, 53.8% UVA). The intensity of the UVB source was measured before each experiment using an IL1700 radiometer and a SED240 UVB detector (International Light, Newburyport, MA) at a distance of 8 cm from the UVB source to the monolayer of cells. Following either sham (nonirradiation, left out on bench top open) or UVB irradiation, the cells were incubated at 371C for 1 hour, and then scraped and sonicated for cell homogenates. For assays involving PGE 2 quantitation, the cells were incubated at 371C for the time indicated in the figure legend prior to removal of the media for PGE 2 immunoassay. In this case, the monolayer was trypsinized for total cell counts to normalize the PGE 2 results.
Immunoblotting
Cells were washed twice with ice-cold phosphate-buffered saline and lysed with radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) containing 0.5 mM Pefabloc SC (Roche Diagnostics, Indianapolis, IN) and 10 mM sodium orthovanadate for 20 minutes on ice. COX-2 protein was separated on 10% SDS-PAGE and expression was determined by immunoblotting with COX-2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ). The expression of COX-2 protein was normalized to the levels of housekeeping protein glyceraldehyde-3-phosphate dehydrogenase.
PGE 2 immunoassay
PGE 2 production was quantitated from SZ95 sebocytes plated in a 24-well dish as previously described using an immunoassay kit (R&D Systems, Minneapolis, MN) (Zhang et al., 2005) .
RNA isolation and quantitative reverse transcription-PCR
Total RNA was first isolated and purified from cultured cells using an RNeasy s minikit (Qiagen Inc., Valencia, CA), according to the manufacturer's protocol. Total RNA quantity, purity, and the absence of ribonuclease digestion were assessed by OD260/280 absorbance measurements and by agarose gel electrophoresis. First-strand DNA synthesis was then performed on 5 mg of RNA using a Superscript FirstStrand Synthesis System (Invitrogen, Carlsbad, CA). Reverse transcription was primed using random hexamers. For quantitative RT-PCR, human COX-2 was selected using a primer design software (PrimerExpress, PE Applied Biosystems, Foster City, CA). The COX-2 forward primer was 5 0 -GAATCATTCACCAGGCAAATTG-3 0 , whereas the reverse primer was 5 0 -TCTGTACTGCGGGTGGAACA-3 0 . To normalize for RNA loading and quality, a separate assay using primers selective for 18S ribosomal RNA was performed. The 18S forward primer was 5 0 -ACATCCAAGGAAGGCAGCAG-3 0 . The 18S reverse primer was 5 0 -TCGTCACTACCTCCCCGG-3 0 . Real-time quantitative RT-PCR was then performed using a Cepheid thermocycler (Fisher Scientific, Pittsburgh, PA). Fluorescent detection of PCR products was quantitated using SyberGreen (Qiagen SyberGreen Quantitect RT-PCR mix, Valencia, CA). The PCR amplification was initiated using a 15 minute 951C incubation to activate the HotStarTaq DNA Polymerase. For 18S PCR, this was followed by 35 cycles with the following thermoprofile: 951C for 30 seconds, 571C for 15 seconds, and 701C for 30 seconds. For COX-2, the cycling parameters were 951C for 15 seconds, 57.51C for 30 seconds, and 721C for 30 seconds. A melt curve analysis and agarose gel electrophoresis was performed to verify the presence of a single amplification product, 60 bp for 18S and 65 bp for the COX-2 product. For quantitative analysis of both COX-2 and 18S, a standard curve was generated using PCR product that was band purified following agarose gel electrophoresis. Importantly, the threshold cycle (C t ) for all samples occurred well within the observed linear range determined using the standard curve. Contaminating DNA in all RNA samples was analyzed by performing qRT-PCR from RNA samples in which a sham reverse transcription reaction was performed (no reverse transcriptase). These no RT controls were either negative or contributed less than 1% of the COX-2 levels for all samples.
Data analysis
Data are presented as mean7standard deviation (SD) of at least three independent experiments. Statistical significance is assessed by the Student's t-test and significance is set as *Po0.05 and **Po0.01.
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